NX210c for ALS – The ALS – “SEALS” Phase 2 Study – ALS ONE

Phase II clinical trial evaluating NX210c drug candidate efficacy in ALS patients (“SEALS”): rational and innovative design. Dr Annette Janus, MD – Chief Medical Officer

The release as fetched from its publisher. axoltis.com ↗